PMC:7787218 / 45-424
Annnotations
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 280-284 | Phenotype | denotes | pain | http://purl.obolibrary.org/obo/HP_0012531 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
17 | 83-130 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
18 | 132-142 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
21 | 64-73 | Disease | denotes | infection | MESH:D007239 |
22 | 280-284 | Disease | denotes | pain | MESH:D010146 |
23 | 286-293 | Disease | denotes | redness | MESH:D003117 |
24 | 299-307 | Disease | denotes | swelling | MESH:D004487 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 0-379 | Sentence | denotes | To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing phase 3 clinical trials.1 Minor local side effects such as pain, redness, and swelling have been observed more frequently with the vaccines than with placebo. |